In a breakthrough study featured in the BMJ, a general medical journal that publishes open-access titles, the live zoster (shingles) vaccine takes centre stage in the quest for sustained wellness. Revealing its peak effectiveness in the initial year post-vaccination, this research unravels a compelling narrative of enduring protection against shingles and its complications, even after a decade, especially for those with weakened immune systems.
Insights for Healthy Living:
When does the live zoster vaccine offer its prime defence?
Discover the vaccine's peak efficacy within the first year, aligning with your journey towards a healthier lifestyle.
How does the vaccine's effectiveness evolve over the years?
Uncover the vaccine's journey, from a 67% shield against herpes zoster infection to a resilient 15% protection after ten years.
Can the live zoster vaccine be your long-term ally?
Delve into the study's revelations, showcasing the vaccine's lasting protection against complications like post-herpetic neuralgia and hospitalisation for herpes zoster.
Embark on a wellness expedition with insights from the Kaiser Permanente study, involving 1.5 million adults aged 50, providing a roadmap for sustained health.
Timeline of Effectiveness:
Initial-year efficacy: A robust 67% defence against herpes zoster infection.
Ongoing journey: Witness the vaccine's resilience, from a 50% stronghold in the second year to a commendable 27% in the eighth year.
Guardianship Against Complications:
For post-herpetic neuralgia, the vaccine maintains a reassuring 41% efficacy after a decade.
Journeying from 5-8 years post-vaccination, hospitalisation for herpes zoster still sees a commendable 53% efficacy.
(With inputs from IANS)